Description
A PDE5 inhibitor (IC50s = 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum, respectively); selective for PDE5 over PDE1 and PDE3 (IC50s = 0.26 and 65 μM, respectively); reverses glucose-induced decreases in ANG1 expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro; increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy; increases ICP/MAP ratio in castrated rats at 20 mg/kg per day; reduces cardiac arrest and resuscitation-induced increases in angiotensin II ACE, ACE2, and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury,
Formal name: 5-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-methyl-3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one, 2-hydroxy-1,2,3-propanetricarboxylate
Synonyms: Apodefil|Tonafil|UK 92480
Molecular weight: 666.7
CAS: 171599-83-0
Purity: ≥98%
Formulation: A crystalline solid
Application||Product Type|Biochemicals|Small Molecule Inhibitors|Phosphodiesterases||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Cardiovascular Diseases|Myocardial Infarction||Research Area|Cardiovascular System|Vasculature|Angiogenesis||Research Area|Cell Biology|Cell Signaling|cGMP Signaling